Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- UCHealth University of Colorado Hospital — Aurora, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Colorado: - University of Colorado Hospital - Anshutz Cancer Pavilion — Aurora, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 3 Recruiting Academic/Other
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and impro…
Sponsor: University of Colorado, Denver
NCT ID: NCT05819853
Sites in Colorado: - University of Colorado Anschutz/Children's Hospital Colorado Aurora — Aurora, Colorado
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Medical Center of the Rockies — Loveland, Colorado
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Colorado: - Site 0135 - Rocky Mountain Cancer Centers — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Colorado: - Rocky Mountain Cancer Center — Littleton, Colorado
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Colorado: - USA01-0 — Wheat Ridge, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…
Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in Colorado: - University of Colorado Denver — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
NCT ID: NCT06386146
Sites in Colorado: - Research Site — Denver, Colorado
Phase 2 Recruiting Academic/Other
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Sponsor: University of Colorado, Denver
NCT ID: NCT05887609
Sites in Colorado: - University of Colorado Hospital — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of thi…
Sponsor: BioNTech SE
NCT ID: NCT07186842
Sites in Colorado: - SCRI at HCA Health One — Denver, Colorado
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Colorado: - Sarah Cannon Research Institute at HealthOne — Denver, Colorado
Phase 1 Recruiting Industry
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chem…
Sponsor: Pheast Therapeutics
NCT ID: NCT06840886
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One — Denver, Colorado
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in Colorado: - Normunity Investigational Site — Denver, Colorado
Phase 1 Recruiting Industry
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06997029
Sites in Colorado: - Local Institution - 0008 — Aurora, Colorado
Phase 1 Recruiting Industry
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor typ…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07503808
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado